IMRX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

IM

Mkt Cap

$232.5M

Volume

710.68K

Next Earnings

November 11th

Loading chart

IM

IMRXImmuneering Corporation Class A Common Stock

IMRX

Pay with—

Available Balance0.00

IM

Mkt Cap

$232.3M

Volume

710.68K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)Immuneering Corporation announced preclinical data demonstrating that atebimetinib, a MEK inhibitor, enhances PD-1 checkpoint blockade in RAS mutant tumor models. The findings support the company's plans to conduct a Phase 2 study combining atebimetinib with PD-1 blockade in lung cancer patients. The poster will be presented at the SITC 41st Annual Meeting in November 2026.GlobeNewswire Inc. · Oct 2, 2026

Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line PatientsFollowing an FDA approval of a second-line pancreatic cancer treatment, Immuneering Corporation reaffirmed its focus on first-line metastatic pancreatic cancer patients. The company is enrolling patients in its Phase 3 MAPKeeper 301 trial evaluating atebimetinib combined with chemotherapy. Previous Phase 2a data showed 17.3-month median overall survival with manageable side effects, with 84% of patients maintaining or gaining weight at three months.GlobeNewswire Inc. · Aug 26, 2026

Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Drop— AZZ, Northrop Grumman, Immuneering In Focus (UPDATED)U.S. stock futures declined on Thursday with investors awaiting Supreme Court ruling on tariffs and December jobs reports. AZZ surged on strong earnings, Northrop Grumman jumped on defense spending proposals, while Immuneering tumbled on disappointing trial data and Phathom dropped following stock offering announcement. Constellation Brands rose on better-than-expected earnings.Benzinga · Jan 8, 2026

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnPImmuneering Corporation announced positive Phase 2a trial results showing 64% overall survival at 12 months for atebimetinib combined with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients, nearly double the 35% benchmark from standard of care. The company plans to initiate its pivotal Phase 3 trial (MAPKeeper 301) in mid-2026, with FDA and EMA alignment already secured on trial design.GlobeNewswire Inc. · Jan 7, 2026

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025Immuneering Corporation will host a conference call to discuss updated overall survival and safety data from a Phase 2a clinical trial of atebimetinib + mGnP in first-line pancreatic cancer patients, with 9 months median follow-up.Benzinga · Sep 26, 2025

Why PepGen Shares Are Trading Higher By 112%; Here Are 20 Stocks Moving PremarketPepGen Inc. experienced a significant 112.4% pre-market stock surge after announcing an underwritten public offering of common stock and pre-funded warrants. Several other stocks showed notable pre-market movements, with some gaining and others declining.Benzinga · Sep 25, 2025

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to SanofiImmuneering Corporation announced a public offering of 18,959,914 Class A common stock shares at $9.23 per share, raising approximately $175 million. Simultaneously, Sanofi will purchase 2,708,559 shares in a private placement transaction.GlobeNewswire Inc. · Sep 25, 2025

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25Immuneering plans to share updated overall survival data for atebimetinib + mGnP in first-line pancreatic cancer patients, with presentations at investor call and scientific conferences highlighting promising early results.GlobeNewswire Inc. · Sep 10, 2025

Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer PatientsImmuneering reported positive data from its ongoing Phase 2a trial of atebimetinib (IMM-1-104) in combination with modified Gemcitabine/nab-Paclitaxel (mGnP) for first-line pancreatic cancer patients, including 94% overall survival at 6 months and a favorable tolerability profile.GlobeNewswire Inc. · Jun 17, 2025

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025Immuneering Corporation announced that it will host a conference call to provide updates from its ongoing Phase 2a clinical trial of IMM-1-104 in first-line pancreatic cancer patients.GlobeNewswire Inc. · Jun 16, 2025

to start trading

IM

IMRXImmuneering Corporation Class A Common Stock

IMRX

Pay with—

Available Balance0.00

Your PositionYou don't own any IMRX yet.

Related Tickers

Earnings